文献速递治疗药物监测与药物基因组学药物相互作用特殊人群用药

利用TDM质谱数据识别质子泵抑制剂并量化CYP2C19基因型患者艾司西酞普兰代谢的表型转化

Reprocessing Mass Spectra from Therapeutic Drug Monitoring to Unveil Proton Pump Inhibitor Use and Quantify Phenoconversion of Escitalopram Metabolism in CYP2C19-Genotyped Patients.
PubMed 文献 · Clin Pharmacol Ther · 2026-10-14

本研究重新处理治疗药物监测(TDM)的高分辨率质谱数据,识别CYP2C19基因型患者中质子泵抑制剂(PPI)合并用药,并量化其对艾司西酞普兰代谢的表型转化。纳入2818例患者,445例(15.8%)使用PPI。无PPI时CYP2C19超快代谢者与慢代谢者艾司西酞普兰代谢比相差4.5倍,而使用泮托拉唑或奥美拉唑/艾司奥美拉唑时该差异分别缩小至2.8倍和1.8倍,提示PPI显著诱导表型转化。

要点

  • PPI合并用药显著改变CYP2C19介导的艾司西酞普兰代谢,奥美拉唑/艾司奥美拉唑影响大于泮托拉唑。
  • TDM质谱数据可回溯识别合并用药,辅助解释基因型-表型不匹配。
  • CYP2C19基因型检测联合TDM代谢比有助于个体化评估艾司西酞普兰暴露。

核心结论

  • PPI对CYP2C19介导的艾司西酞普兰代谢显示显著的表型转化,奥美拉唑/艾司奥美拉唑作用强于泮托拉唑。
  • 重新处理TDM高分辨率质谱可识别 interacting comedication,展示精准医学应用潜力。

研究设计与样本

  • 回顾性研究,纳入挪威奥斯陆TDM/药物基因组学联合实验室数据库中具有艾司西酞普兰TDM数据和CYP2C19基因型的患者2818例。
  • 通过精确质量和碎片检测重新处理高分辨率质谱,使用mzCloud参考库识别泮托拉唑、艾司奥美拉唑/奥美拉唑或兰索拉唑合并用药。
  • 按CYP2C19表型分为正常代谢者(NMs)、中间代谢者(IMs)、慢代谢者(PMs)、快代谢者(RMs)和超快代谢者(UMs)。
  • 主要结局指标为UMs与PMs的N-去甲基艾司西酞普兰/艾司西酞普兰代谢比(MR)。

主要发现

  • 共纳入2818例患者,其中2373例无PPI,445例(15.8%)使用PPI;女性占64.2%。
  • CYP2C19表型分布:NMs 39.3%,IMs 29.3%,PMs 2.6%,RMs 24.6%,UMs 4.2%。
  • 无PPI时,CYP2C19 UMs与PMs的艾司西酞普兰MR相差4.5倍(P < 0.001)。
  • 泮托拉唑使用者中UMs与PMs的MR差异为2.8倍(P < 0.001)。
  • 艾司奥美拉唑/奥美拉唑使用者中UMs与PMs的MR差异为1.8倍(P = 0.2)。

临床怎么用

  • 临床解读艾司西酞普兰TDM结果时,应关注合并PPI对CYP2C19表型的影响,尤其奥美拉唑/艾司奥美拉唑可能增强表型转化。
  • 对CYP2C19基因型与TDM代谢比不一致的患者,可考虑回溯质谱数据识别未记录的PPI合并用药。

局限性

  • 研究为回顾性设计,PPI识别依赖质谱库匹配,可能存在未识别或误识别。
  • 艾司奥美拉唑/奥美拉唑组UMs与PMs的MR差异P = 0.2,未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Escitalopram is a frequently prescribed antidepressant drug. CYP2C19 genotype is a major determinant of escitalopram metabolism and treatment outcome. However, real-life studies show a high degree of genotype-phenotype mismatch in escitalopram metabolism. The present study aimed to identify comedication with proton pump inhibitors (PPIs) and quantify phenoconversion of escitalopram metabolism in CYP2C19-genotyped patients by reprocessing high-resolution mass spectra from therapeutic drug monitoring (TDM) analyses. Patients were included from a combined TDM/pharmacogenetics (PGx) laboratory facility in Oslo, Norway. TDM profiles of escitalopram and CYP2C19 genotypes were available in the laboratory database. Reprocessing of high-resolution mass spectra by exact mass and fragment detection identified possible comedication with pantoprazole, esomeprazole/omeprazole or lansoprazole using mzCloud reference library. Patients were grouped as normal metabolizers (NMs), intermediate metabolizers (IMs), poor metabolizers (PMs), rapid metabolizers (RM), or ultrarapid metabolizers (UM). Primary outcome measure was N-desmethylescitalopram-to-escitalopram metabolic ratio (MR; CYP2C19 biomarker) in UMs vs. PMs. 2818 patients were included, constituting 2373 without and 445 (15.8%) with PPIs. Most patients were females (64.2%). Regarding CYP2C19 phenotype distribution, the cohort comprised 39.3% NMs, 29.3% IMs, 2.6% PMs, 24.6% RMs, and 4.2% UMs. Escitalopram MR was 4.5-fold higher in CYP2C19 UMs vs. PMs without PPIs (P < 0.001), while this difference was 2.8-fold in pantoprazole users (P < 0.001), and 1.8-fold in esomeprazole/omeprazole users (P = 0.2). In conclusion, PPIs show significant phenoconversion of CYP2C19-mediated escitalopram metabolism with esomeprazole/omeprazole exhibiting a stronger effect than pantoprazole. The novel method for identification of interacting comedications in TDM samples illustrates the innovative potential of high-resolution mass spectrometry in precision medicine.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hole K, Wollmann BM, Stingl JC, et al. Reprocessing Mass Spectra from Therapeutic Drug Monitoring to Unveil Proton Pump Inhibitor Use and Quantify Phenoconversion of Escitalopram Metabolism in CYP2C19-Genotyped Patients. Clin Pharmacol Ther. 2026. PMID: 42876187. doi:10.1002/cpt.70506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。